Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure.
| Title: | Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure. |
|---|---|
| Authors: | Huynh TLT; Department of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, Vietnam.; Pham PT; Department of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, Vietnam.; Tran HD; Department of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, Vietnam.; Tran ND; Department of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, Vietnam.; Tran DV; Department of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, Vietnam.; Tran BLT; Department of Internal Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Ninh Kieu, Vietnam.; Tran KDD; Department of Internal Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Ninh Kieu, Vietnam.; Ngo TH; Department of Internal Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Ninh Kieu, Vietnam.; Tran SK; Department of Internal Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Ninh Kieu, Vietnam. |
| Source: | PeerJ [PeerJ] 2024 Nov 29; Vol. 12, pp. e18595. Date of Electronic Publication: 2024 Nov 29 (Print Publication: 2024). |
| Publication Type: | Journal Article; Comparative Study |
| Language: | English |
| Journal Info: | Publisher: PeerJ Inc Country of Publication: United States NLM ID: 101603425 Publication Model: eCollection Cited Medium: Internet ISSN: 2167-8359 (Electronic) Linking ISSN: 21678359 NLM ISO Abbreviation: PeerJ Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Corte Madera, CA : PeerJ Inc. |
| MeSH Terms: | Uric Acid*/blood ; Losartan*/therapeutic use ; Benzhydryl Compounds*/therapeutic use ; Heart Failure*/drug therapy ; Heart Failure*/blood ; Glucosides*/therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Drug Therapy, Combination*; Humans ; Male ; Female ; Aged ; Middle Aged ; Cross-Sectional Studies ; Treatment Outcome |
| Abstract: | Background: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors, and Angiotensin II Receptor Antagonists (ARBs) also have the effect of reducing serum uric acid but few studies worldwide assessed.; Objective: Evaluate the effectiveness of serum uric acid lowering treatment of SGLT2 inhibitors, and ARB in heart failure (HF) patients.; Methods: We conducted a cross-sectional analysis study with 8 weeks of follow-up on 733 heart failure (HF) patients treated at Can Tho Central General Hospital from January 2023 to March 2024. Patients enrolled in the study were examined and received losartan (Group A) or dapagliflozin (Group B) monotherapy or losartan and dapagliflozin combined therapy (Group C). The uric acid concentration group was defined into three subgroups with tertile 1 from smallest to quartile (Q) 1, tertile 2 from Q2 to Q3, and tertile 3 from Q3 to the largest value.; Results: After 8 weeks of treatment, the uric acid reduction effect between groups A, B, and C showed that the combination group had the optimal reducing effect compared to losartan and dapagliflozin monotherapy with the mean difference being -229.62 ± 76.65 µmol/L, -217.00 ± 146.17 µmol/L, and -284.43 ± 136.32 µmol/L, respectively. In total, combination therapy showed the best reduction outcome in the population of male, female, patients with type 2 diabetes mellitus (T2DM), and dyslipidemia with the mean difference ranging from -226.21 ± 74.65 µmol/L to -231.85 ± 76.28 µmol/L and -209.62 ± 184.94 µmol/L to -225.75 ± 78.53 µmol/L and -273.02 ± 204.54 µmol/L to -308.93 ± 72.97 µmol/L in group A, B, and C, respectively.; Conclusion: The optimal therapy for reducing uric acid levels in HF patients was the combination of losartan and dapagliflozin, and the effectiveness did not change through sex, T2DM, and dyslipidemia patients.; (© 2024 Huynh et al.) |
| Competing Interests: | The authors declare that they have no competing interests. |
| References: | Circulation. 2002 Dec 17;106(25):3143-421. (PMID: 12485966); Eur J Heart Fail. 2022 Jun;24(6):1066-1076. (PMID: 35064721); Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31. (PMID: 31862745); Eur Heart J. 2022 Sep 21;43(36):3435-3446. (PMID: 35788657); J Cardiol. 2023 Jul;82(1):57-61. (PMID: 37030532); Int J Cardiol. 2011 Sep 1;151(2):143-7. (PMID: 20542341); J Am Soc Echocardiogr. 2018 Mar;31(3):241-274. (PMID: 29502588); Cardiovasc Diabetol. 2022 May 14;21(1):75. (PMID: 35568879); J Clin Pharm Ther. 2020 Dec;45(6):1264-1270. (PMID: 32737930); J Renin Angiotensin Aldosterone Syst. 2021 Aug 25;2021:2214978. (PMID: 34527078); Front Endocrinol (Lausanne). 2023 Apr 05;14:1131566. (PMID: 37091841); J Assoc Physicians India. 2008 Oct;56:759-62. (PMID: 19263700); Clin Exp Hypertens. 2015;37(3):192-6. (PMID: 25051056); Nephrol Dial Transplant. 2001 May;16(5):1034-7. (PMID: 11328912); Circulation. 2010 Feb 23;121(7):e46-e215. (PMID: 20019324); J Pers Med. 2022 Dec 22;13(1):. (PMID: 36675682); Arch Med Sci. 2022 Aug 30;18(5):1133-1156. (PMID: 36160355); Herz. 2022 Feb;47(1):12-18. (PMID: 34825250); Eur Heart J. 2018 Sep 1;39(33):3021-3104. (PMID: 30165516); N Engl J Med. 2019 Nov 21;381(21):1995-2008. (PMID: 31535829); Medicina (Kaunas). 2024 Jun 30;60(7):. (PMID: 39064509); J Am Coll Cardiol. 2005 Sep 20;46(6):e1-82. (PMID: 16168273); Clin Chem Lab Med. 2001 Sep;39(9):822-6. (PMID: 11601680); Addiction. 2018 Jun;113(6):1019-1029. (PMID: 29486097); Am J Med. 2020 Jun;133(6):e237-e248. (PMID: 31747542); QJM. 2000 Nov;93(11):707-13. (PMID: 11077027) |
| Contributed Indexing: | Keywords: Combination therapy; Dapagliflozin; Heart failure; Losartan; Uric acid reduction |
| Molecular Sequence: | figshare 10.6084/m9.figshare.27291606.v1 |
| Substance Nomenclature: | 1ULL0QJ8UC (dapagliflozin); 268B43MJ25 (Uric Acid); JMS50MPO89 (Losartan); 0 (Benzhydryl Compounds); 0 (Glucosides); 0 (Sodium-Glucose Transporter 2 Inhibitors) |
| Entry Date(s): | Date Created: 20241203 Date Completed: 20241203 Latest Revision: 20241203 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11610471 |
| DOI: | 10.7717/peerj.18595 |
| PMID: | 39624121 |
| Database: | MEDLINE |
Journal Article; Comparative Study